|
|
| | 2-Piperidinecarboxylic acid, 1-[[2,6-dimethoxy-4-[(2-methyl[1,1'-biphenyl]-3-yl)methoxy]phenyl]methyl]-, (2S)- Basic information |
| Product Name: | 2-Piperidinecarboxylic acid, 1-[[2,6-dimethoxy-4-[(2-methyl[1,1'-biphenyl]-3-yl)methoxy]phenyl]methyl]-, (2S)- | | Synonyms: | 2-Piperidinecarboxylic acid, 1-[[2,6-dimethoxy-4-[(2-methyl[1,1'-biphenyl]-3-yl)methoxy]phenyl]methyl]-, (2S)-;PD1-PDL1 inhibitor 1;PD-1PD-L1 inhibitor;(2S)-1-[[2,6-Dimethoxy-4-[(2-methyl[1,1'-biphenyl]-3-yl)methoxy]phenyl]methyl]-2-piperidinecarboxylic acid;avelumab/PD-L1;T3655;(2S)-1-{2,6-Dimethoxy-4-[(2-methyl-3-biphenylyl)methoxy]benzyl}-2-piperidinecarboxylic acid;PD1-PDL1 inhibitor 1 (PD1-PDL1-IN1) | | CAS: | 1675201-83-8 | | MF: | C29H33NO5 | | MW: | 475.58 | | EINECS: | | | Product Categories: | | | Mol File: | 1675201-83-8.mol | ![2-Piperidinecarboxylic acid, 1-[[2,6-dimethoxy-4-[(2-methyl[1,1'-biphenyl]-3-yl)methoxy]phenyl]methyl]-, (2S)- Structure](CAS/20180702/GIF/1675201-83-8.gif) |
| | 2-Piperidinecarboxylic acid, 1-[[2,6-dimethoxy-4-[(2-methyl[1,1'-biphenyl]-3-yl)methoxy]phenyl]methyl]-, (2S)- Chemical Properties |
| Boiling point | 630.2±55.0 °C(Predicted) | | density | 1.182±0.06 g/cm3(Predicted) | | storage temp. | -20°C | | solubility | Soluble in DMSO (up to at least 25 mg/ml) or in Ethanol (up to 20 mg/ml) | | pka | 2.34±0.20(Predicted) | | form | solid | | color | White | | Stability: | Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months. |
| | 2-Piperidinecarboxylic acid, 1-[[2,6-dimethoxy-4-[(2-methyl[1,1'-biphenyl]-3-yl)methoxy]phenyl]methyl]-, (2S)- Usage And Synthesis |
| Description | PD-1/PD-L1 Inhibitor 1 (1675201-83-8) inhibits (IC50 = <100nM) the formation of the PD-1/PD-L1 complex via binding to PD-L1 and inducing dimerization.1 | | Uses | BMS-1 is a PD-L1 inhibitor which is used in combination with LIF inhibitors for the treatment of cancers. | | in vitro | pd-1/pd-l1 inhibitor 1 has been identified to be a potent and selective small molecule inhibitor blocking the interaction of programmed cell death protein 1 (pd-1) with its ligand protein (pd-l1). pd-1/pd-l1 inhibitor 1 was also found to act as an immunomodulator. in preclinical studies, pd-1/pd-l1 inhibitor 1 was able to block pd-1/pd-ll interactions with an ic50 value between 6 and 100 nm, which was measured by a homogenous time-resolved fluorescence (htrf) binding assay. thus, pd-1/pd-l1 inhibitor 1 might potentially be used for the treatment of cancer as well as infectious diseases, such as hepatitis c [1]. | | IC 50 | 0.006-0.10 μm | | References | 1) Chupak?et al. (2015), Compounds Useful as Immunomodulators; WO2015/034820 |
| | 2-Piperidinecarboxylic acid, 1-[[2,6-dimethoxy-4-[(2-methyl[1,1'-biphenyl]-3-yl)methoxy]phenyl]methyl]-, (2S)- Preparation Products And Raw materials |
|